Versteijne E, et al. - Researchers assessed survival by intention to treat in a comparison of upfront surgery vs neoadjuvant treatment in resectable or borderline resectable pancreatic cancer. They identified the relevant studies from MEDLINE, Embase and the Cochrane Library. The studies analyzed were focused on median overall survival by intention to treat in these patients treated with or without neoadjuvant treatment. The studies also reported on overall and R0 resection rate, pathological lymph node rate, reasons for unresectability and toxicity of neoadjuvant treatment. Overall survival by intention to treat appeared to be improved with neoadjuvant treatment, however, lower overall resection rates for resectable or borderline resectable pancreatic cancer were reported.